Abstract
Purpose
To compare the sensitivity of 123I-metaiodobenzylguanidine (MIBG) SPECT and 68Ga-DOTATATE PET/CT in detecting phaeochromocytomas (PCC) and paragangliomas (PGL) in the initial diagnosis and follow-up of patients with PCC and PGL disease.
Methods
Retrospective analysis of 15 patients with PCC/PGL who had contemporaneous 123I-MIBG and 68Ga-DOTATATE imaging.
Results
Of the 15 patients in the series, 8 were concordant with both modalities picking up clinically significant lesions. There were no patients in whom both modalities failed to pick up clinically significant lesions. There was discordance in seven patients: 5 had positive 68Ga-DOTATATE and negative 123I-MIBG, and 2 (12 and 14) had negative 68Ga-DOTATATE and positive 123I-MIBG. Utilizing 123I-MIBG as the gold standard, 68Ga-DOTATATE had a sensitivity of 80 % and a positive predictive value of 62 %. The greatest discordance was in head and neck lesions, with the lesions in 4 patients being picked up by 68Ga-DOTATATE and missed by 123I-MIBG. On a per-lesion analysis, cross-sectional (CT and MRI) and 68Ga-DOTATATE was superior to 123I-MIBG in detecting lesions in all anatomical locations, and particularly bony lesions.
Conclusion
First, 68Ga-DOTATATE should be considered as a first-line investigation in patients at high risk of PGL and metastatic disease, such as in the screening of carriers for mutations associated with familial PGL syndromes. Second, if 123I-MIBG does not detect lesions in patients with a high pretest probability of PCC or PGL, 68Ga-DOTATATE should be considered as the next investigation. Third, 68Ga-DOTATATE hould be considered in preference to 123I-MIBG in patients in whom metastatic spread, particularly to the bone, is suspected.
References
Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3(2):92–102. doi:10.1038/ncpendmet0396.
Carrasquillo JA, Chen CC. Molecular imaging of neuroendocrine tumors. Semin Oncol. 2010;37(6):662–79. doi:10.1053/j.seminoncol.2010.10.015.
Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003;88(11):5150–7.
Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49(10):1613–9. doi:10.2967/jnumed.108.052373.
Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13(4):769–75. doi:10.1007/s11307-010-0396-8.
Naswa N, Sharma P, Nazar AH, Agarwal KK, Kumar R, Ammini AC, et al. Prospective evaluation of (68)Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol. 2012;22(3):710–9. doi:10.1007/s00330-011-2289-x.
Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95(6):2800–10. doi:10.1210/jc.2009-2352.
van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86(2):685–93.
Bhatia KS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol. 2008;69(2):181–8. doi:10.1111/j.1365-2265.2008.03256.x.
Charrier N, Deveze A, Fakhry N, Sebag F, Morange I, Gaborit B, et al. Comparison of [111In]-pentetreotide-SPECT and [18F]-FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol. 2011;74(1):21–9. doi:10.1111/j.1365-2265.2010.03893.x.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maurice, J.B., Troke, R., Win, Z. et al. A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39, 1266–1270 (2012). https://doi.org/10.1007/s00259-012-2119-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-012-2119-7